Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Other Accumulated Expenses (2017 - 2022)

Lipocine's Other Accumulated Expenses history spans 4 years, with the latest figure at $1.0 million for Q1 2022.

  • For Q1 2022, Other Accumulated Expenses changed N/A year-over-year to $1.0 million; the TTM value through Mar 2022 reached $1.0 million, changed N/A, while the annual FY2021 figure was $1.0 million, N/A changed from the prior year.
  • Other Accumulated Expenses reached $1.0 million in Q1 2022 per LPCN's latest filing, roughly flat from $1.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $4.2 million in Q1 2018 to a low of $1.0 million in Q3 2021.
  • Average Other Accumulated Expenses over 3 years is $2.0 million, with a median of $1.0 million recorded in 2021.